Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17728906 | 1.00 | LIPA (0.38) | LIPAEPHX1GLAEPHX2HSD11B1 | |
| SCHEMBL3188180 | 1.00 | LIPA (0.38) | LIPAEPHX1GLAEPHX2HSD11B1 | |
| SCHEMBL6854175 | 0.84 | LIPA (0.31) | LIPA | |
| SCHEMBL6854599 | 0.84 | LIPA (0.31) | LIPA | |
| SCHEMBL17084625 | 0.82 | CES2 (0.33) | — | |
| SCHEMBL17084624 | 0.82 | CES2 (0.33) | — | |
| SCHEMBL13555096 | 0.80 | LIPA (0.32) | LIPA | |
| SCHEMBL3594834 | 0.80 | ALDH1A1 (0.41) | — | |
| SCHEMBL28143602 | 0.80 | — | — | |
| SCHEMBL6854630 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
| US-4954489-A | ACYLATION | BEECHAM GROUP P.L.C. (GB) | 1990-09-04 | — | — | US | disclosed |
| EP-0337643-A2 | 6-Substituted acrylamido penicillanic acid derivatives, preparation and use | BEECHAM GROUP PLC (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | LIPA 247/4885EPHX1 1557/4885GLA 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.